HomeSmall Caps
Share

AstraZeneca-backed biotech Summit plunges after FDA rejection of lung cancer therapy

Maria Dranishnikova

Maria Dranishnikova

Oninvest reporter
Summit said the FDA declined to approve its drug ivonescimab in combination with chemotherapy for non-small cell lung cancer / Photo: Shutterstock.com

Summit said the FDA declined to approve its drug ivonescimab in combination with chemotherapy for non-small cell lung cancer / Photo: Shutterstock.com

Shares of biotech Summit Therapeutics plunged more than 16% on the Nasdaq on Monday to hit a two-year low. The company said the U.S. Food and Drug Administration had declined to approve its lung cancer treatment. Just two months ago, pharmaceutical giant AstraZeneca announced plans to invest $2 billion in Summit.

Details

Summit shares tumbled more than 16% on Nasdaq on Monday to $11.82 apiece, their lowest close in more than two years. The stock fell after Summit said the FDA had declined to approve its drug ivonescimab in combination with chemotherapy for non-small cell lung cancer.

The available data failed to convince the FDA that the treatment helps patients live longer, Summit said in its release. Ivonescimab combined with chemotherapy reduced the risk of disease progression or death by 48% versus chemotherapy alone.

The FDA cited the lack of a statistically significant improvement in overall survival, which measures how long patients live after starting treatment. Overall survival is considered the “gold standard” in clinical trials because death can be measured objectively, Barron’s explains. Summit gave no plans or timetable for resubmitting its application.

About ivonescimab

Ivonescimab is a bispecific antibody. Unlike conventional antibodies, it targets two proteins at once: PD-1, which helps cancer cells evade the immune system, and VEGF, which tumors use to grow blood vessels. In 2022, Summit agreed to acquire exclusive rights from China’s Akeso to develop and commercialize ivonescimab in the U.S., Canada, Europe, and Japan. In June 2024, the license was expanded to cover Latin America, the Middle East, and Africa. Akeso retained the rights elsewhere and has marketed the drug in China since 2024.

In late September, ahead of the FDA decision, AstraZeneca signed an agreement with Summit to invest $2 billion in the biotech and collaborate on studies combining ivonescimab with other drugs. If the FDA had approved ivonescimab, AstraZeneca could have benefited from its U.S. launch through its stake in Summit, Barron’s reported.

What analysts say

At least three Wall Street houses, Evercore ISI Group, Barclays, and Citigroup, cut their target prices for Summit after the FDA declined to approve ivonescimab, according to Yahoo Finance data. Barclays made the steepest cut, lowering its TP by 10% to $18 per share, implying 52% upside. It rates the stock “equal weight.”

Citi analyst Yigal Nochomovitz said the FDA decision had been “widely expected” on Wall Street, Barron’s reports. Investors appeared more disappointed by the outlook for the broader class of drugs that includes Summit’s treatment. Citi has a “buy” rating on Summit with a TP of $42 per share, down from $43 per share and implying 255% upside.

Summit has 12 “buy” calls versus six “hold” ratings from Wall Street analysts, according to MarketWatch data. The average target price is $29.71 per share, implying 151% upside from the last close.

Share

Trending

Stock Screener
Buy
Sell
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
Small Caps
Investment and Finance News